

Laparoscopic versus Open Ventral Hernia repair using a classical versus Collagen MESH (Surgisis Gold®): a European Multicenter Two Factorial Randomized Controlled Trial (LAPSIS Trial)

Submission date 22/06/2005	Recruitment status Stopped	☐ Prospectively registered ☐ Protocol
Registration date 15/09/2005	Overall study status Stopped	☐ Statistical analysis plan ☒ Results
Last Edited 18/12/2020	Condition category Surgery	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Marc Miserez

Contact details
Herestraat 49
Leuven
Belgium
3000

Additional identifiers

Protocol serial number
KKSK-4711

Study information

Scientific Title
Laparoscopic versus Open Ventral Hernia repair using a classical versus Collagen MESH (Surgisis Gold®): a European Multicenter Two Factorial Randomized Controlled Trial (LAPSIS Trial)

Acronym

LAPSIS

Study objectives

1. Surgisis Gold (perforated) is non-inferior as compared to conventional meshes
2. Laparoscopic is superior to open ventral hernia repair in regards of the development of major complications

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 30/09/2013: Medical Ethics Committee of the UZ KULeuven, 17/01/2005, ref: ML2925

Primary study design

Interventional

Study design

Multicenter two factorial randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Primary or incisional ventral hernia

Interventions

Collagen mesh (Surgisis Gold® [perforated]) versus conventional mesh and laparoscopic versus open ventral hernia repair.

Updated 10/09/2009: this trial has stopped recruiting and the last patient was randomised on 21/07/2009. Follow-up is ongoing for the next three years and the date of last patient out (LPO) is anticipated for August 2012. The anticipated end date of this trial was changed from 31/05/2009 to reflect this.

Updated 13/09/2013: follow-up has ended and the database has been locked.

Intervention Type

Procedure/Surgery

Phase

Not Specified

Primary outcome(s)

Major complication (hernia recurrence, prosthetic infection, re-operation) rate within three years after surgery

Key secondary outcome(s)

1. Early (first 30 days postoperatively) and late (up to three years postoperatively) local complication rate (wound infection, wound dehiscence, wound sinus, fistula formation, bleeding,

- hematoma, seroma formation, peritonitis, mechanical obstruction, ileus, other)
2. Early (first 30 days postoperatively) general complication rate (all adverse events other than listed under local complications: thromboembolic events, cardiac, respiratory, other)
 3. Time to failure (= major complication)
 4. Chronic abdominal wall pain (Von Korff chronic pain questionnaire; preoperatively, one and three years postoperatively)
 5. Chronic discomfort e.g. abdominal wall stiffness (visual analogue scale [VAS]; preoperatively and three years postoperatively)
 6. Mortality (up to three years postoperatively)
 7. Incidence of and cause for conversion in the laparoscopy group

Completion date

31/08/2012

Reason abandoned (if study stopped)

Objectives no longer viable

Eligibility

Key inclusion criteria

1. Elective repair of ventral (including umbilical) hernia with need for mesh repair
2. Age ≥ 18 years
3. Male and female patients may participate
4. Minimal hernia orifice diameter ≥ 4 cm
5. Largest hernia orifice ≤ 10 cm
6. Eligibility to laparoscopic mesh repair
7. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Total final enrolment

253

Key exclusion criteria

1. Medical or surgical contraindication to general anesthesia
2. Severe comorbidity (American Society of Anesthesiologists [ASA] physical status classification ≥ 4)
3. Pregnancy
4. Emergency surgery for incarcerated irreducible hernia
5. Previous mesh repair at the same site

6. Hernia orifice <3 cm away from costal margin/sternum and/or pubis
7. Lumbar hernia
8. Parastomal hernia
9. Need for more than one mesh covering the hernia orifice
10. Need for a mesh larger than 20 cm x 20 cm or 22 cm x 13 cm
11. Crohns disease
12. Life expectancy less than 12 months
13. Chemotherapy within the last four weeks
14. Radiotherapy within the last two months
15. Previous abdominal radiotherapy
16. Known allergy against porcine materials
17. Marfans syndrome
18. Child B or C liver disease
19. Morbid obesity (body mass index [BMI] $\geq 40 \text{ kg/m}^2$)
20. Non-compliance
21. Simultaneous participation in other interventional trials interfering with one of the approaches in this trial
22. Previous participation in this trial

Date of first enrolment

01/07/2005

Date of final enrolment

31/08/2012

Locations

Countries of recruitment

Austria

Belgium

Croatia

Denmark

Germany

Greece

Hungary

Italy

Netherlands

Poland

Portugal

Study participating centre
Herestraat 49
Leuven
Belgium
3000

Sponsor information

Organisation
Individual Sponsor (Germany)

Funder(s)

Funder type
Industry

Funder Name
Cook Biotech Inc. (USA)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2021	18/12/2020	Yes	No